EPN3: A Potential Drug Target and Biomarker (G55040)

Target Name: EPN3

NCBI ID: G55040

EPN3

EPN3: A Potential Drug Target and Biomarker

Epigenetic regulation is a critical process that plays a vital role in cellular development, tissue homeostasis, and disease progression. One of the key epigenetic modifiers that has garnered significant attention in recent years is epinodonitrile (EPN3), an enzyme that adds a methyl group to the protein p16INK4a. p16INK4a is a key regulator of cell cycle progression and has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of EPN3 as a potential drug target and biomarker has significant implications for the development of new therapies in these fields.

The p16INK4a gene encodes a protein that plays a critical role in regulating cell cycle progression and has been implicated in numerous diseases. It is a 21-kDa protein that is expressed in most tissues and cells. The protein is composed of three isoforms, p16INK4a, p16INK4b, and p16INK4b2, which have different half-lives and functions. p16INK4a is the most abundant isoform and is involved in the regulation of cell cycle progression, apoptosis, and DNA damage repair. p16INK4b is involved in the regulation of cell adhesion and p16INK4b2 is involved in the regulation of cell migration.

EPN3 is an enzyme that adds a methyl group to the protein p16INK4a. The methylation of p16INK4a has been shown to alter its stability and function. Methylation of p16INK4a has been shown to inhibit its phosphorylation and subsequent activation, which results in the stability of the protein and its ability to perform its function.

EPN3 has been shown to play a critical role in the regulation of cell cycle progression and has been implicated in numerous diseases. For example, studies have shown that high levels of EPN3 are associated with the development of cancer. Additionally, EPN3 has been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The exact mechanisms by which EPN3 contributes to these diseases are not well understood, but it is clear that it plays a significant role.

As a potential drug target, EPN3 is an attractive target for small molecule inhibitors. Studies have shown that EPN3 is a druggable protein and that small molecule inhibitors have the potential to significantly reduce its expression and activity. Additionally,EPN3 has a relatively high safety profile, which has facilitated its use as a drug target.

In addition to its potential as a drug target, EPN3 has also been shown to be a potential biomarker. The methylation of p16INK4a has been shown to be a sensitive biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Studies have shown thatEPN3 is significantly altered in these diseases and that these changes are associated with the development of these diseases.

In conclusion, EPN3 is a promising drug target and biomarker that has significant implications for the development of new therapies in the fields of cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of EPN3 as a potential drug target and biomarker has significant implications for the development of new therapies in these fields and has the potential to revolutionize the treatment of these diseases. Further research is needed to fully understand the role of EPN3 in these diseases and to develop effective small molecule inhibitors.

Protein Name: Epsin 3

The "EPN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets